MedTrace Logo

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients

NCT01832116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-05-03

No results posted yet for this study

Summary

The purpose of this multicenter imaging sub study is to evaluate the biodistribution and organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or platinum-resistant ovarian cancer. MMOT0530A is a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer. Subsequent to imaging with 89Zr-MMOT0530A, patients will be treated with DMOT4039A in the DMO4993g protocol (clinicaltrials.gov identifier NCT01469793) after this study. DMOT4039A is an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE). By imaging patients with the monoclonal antibody MMOT0530A before treatment, the correlation between tumor uptake of 89Zr-MMOT0530A and response to DMOT4039A therapy will be assessed.

Conditions

  • Ovarian Neoplasms
  • Ovarian Diseases
  • Adnexal Diseases
  • Pancreatic Neoplasms
  • Digestive System Neoplasms
  • Digestive System Diseases
  • Pancreatic Diseases

Interventions

DRUG

89Zr-MMOT0530A

Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Elisabeth G. de Vries, MD PhD · University Medical Center Groningen

  • Henk M Verheul, MD PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832116 on ClinicalTrials.gov